Affiliation: University of Rome La Sapienza
Giannini G, Ristori E, Cerignoli F, Rinaldi C, Zani M, Viel A, et al
. Human MRE11 is inactivated in mismatch repair-deficient cancers. EMBO Rep. 2002;3:248-54 pubmed
..Our findings identify MRE11 as a novel and major target for inactivation in mismatch repair-defective cells and suggest its impairment may contribute to the development of colorectal cancer. ..
Petroni M, Sardina F, Infante P, Bartolazzi A, Locatelli E, Fabretti F, et al
. MRE11 inhibition highlights a replication stress-dependent vulnerability of MYCN-driven tumors. Cell Death Dis. 2018;9:895 pubmed publisher
Giannini G, Capalbo C, Ristori E, Ricevuto E, Sidoni T, Buffone A, et al
. Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families. Breast Cancer Res Treat. 2006;100:83-91 pubmed
..Finally in hereditary breast cancer families with three or more female breast cancer cases we observed a low mutation prevalence and a significant association with BRCA2 mutations. ..
Belardinilli F, Capalbo C, Buffone A, Petroni M, Colicchia V, Ferraro S, et al
. Validation of the Ion Torrent PGM sequencing for the prospective routine molecular diagnostic of colorectal cancer. Clin Biochem. 2015;48:908-10 pubmed publisher
..The IT-PGM is a valid, flexible, sensitive and economical method alternative to the Sanger sequencing in routine diagnostics to select patients for anti-epidermal growth factor receptor therapy for metastatic CRC. ..
Silvestri V, Barrowdale D, Mulligan A, Neuhausen S, Fox S, Karlan B, et al
. Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res. 2016;18:15 pubmed publisher
..e., high histologic grade). These findings could lead to the development of gender-specific risk prediction models and guide clinical strategies appropriate for MBC management. ..
Prodosmo A, Buffone A, Mattioni M, Barnabei A, Persichetti A, De Leo A, et al
. Detection of ATM germline variants by the p53 mitotic centrosomal localization test in BRCA1/2-negative patients with early-onset breast cancer. J Exp Clin Cancer Res. 2016;35:135 pubmed publisher
..These data validate p53-MCL as reliable and specific test for germline ATM variants, confirm ATM as breast cancer susceptibility gene, and highlight a possible association with breast/thyroid cancers. ..
Giannini G, Cerignoli F, Mellone M, Massimi I, Ambrosi C, Rinaldi C, et al
. High mobility group A1 is a molecular target for MYCN in human neuroblastoma. Cancer Res. 2005;65:8308-16 pubmed
..Finally, HMGA1 repression by RNA interference reduced neuroblastoma cell proliferation, indicating that HMGA1 is a novel MYCN target gene relevant for neuroblastoma tumorigenesis. ..